Vitiligo: An immune disease and its emerging mesenchymal stem cell therapy paradigm

Meng Zhang,Tingting Xia,Fengqin Lin,Jiang Yu,Ying Yang,Wei Lei,Tao Zhang
DOI: https://doi.org/10.1016/j.trim.2022.101766
Abstract:Melanocyte damage, innate immune response, adaptive immune response, and immune inflammatory microenvironment disorders are involved in the development of the immunological pathogenic mechanism of vitiligo. Mesenchymal stem cells are considered an ideal type of cells for the treatment of vitiligo owing to their low immunogenicity, lower rates of transplant rejection, and ability to secrete numerous growth factors, exosomes, and cytokines in vivo. The regulation of signaling pathways related to oxidative stress and immune imbalance in the immunological pathogenesis of vitiligo can improve the immune microenvironment of tissue injury sites. In addition, co-transplantation with melanocytes can reverse the progression of vitiligo. Therefore, continuous in-depth research on the immunopathogenic mechanism involved in this disease and mesenchymal stem cell-based therapy is warranted for the treatment of vitiligo in the future.
What problem does this paper attempt to address?